Gallus Biopharmaceuticals Receives Majority Investment from Ridgemont Equity Partners
May 18, 2011
About Gallus BioPharmaceuticalsGallus Biopharmaceuticals is a premier biologics contract manufacturing organization based in St. Louis, MO, which operates an FDA-approved, commercially-certified facility.
About Ridgemont Equity Partners
Ridgemont Equity Partners is a Charlotte-based middle market buyout and growth equity investor. Since 1993, the principals of Ridgemont have invested over $5 billion. The firm focuses on equity investments up to $250 million and utilizes a proven, industry-focused investment approach and repeatable value creation strategies. Ridgemont’s most recent flagship fund, REP III, was formed in 2018 and has $1.65B of committed capital.